Trials / Completed
CompletedNCT04172246
Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies
A Phase 1/2 Study of Zanubrutinib in Japanese Patients With Mature B-Cell Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample size.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zanubrutinib | Zanubrutinib at 160 mg orally twice daily |
Timeline
- Start date
- 2020-01-29
- Primary completion
- 2023-05-10
- Completion
- 2025-06-30
- First posted
- 2019-11-21
- Last updated
- 2025-11-21
Locations
15 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04172246. Inclusion in this directory is not an endorsement.